BACKGROUND: We sought to provide a contemporary picture of the presentation, etiology, and outcome of infective endocarditis (IE) in a large patient cohort from multiple locations worldwide. METHODS: Prospective cohort study of 2781 adults with definite IE who were admitted to 58 hospitals in 25 countries from June 1, 2000, through September 1, 2005. RESULTS: The median age of the cohort was 57.9 (interquartile range, 43.2-71.8) years, and 72.1% had native valve IE. Most patients (77.0%) presented early in the disease (<30 days) with few of the classic clinical hallmarks of IE. Recent health care exposure was found in one-quarter of patients. Staphylococcus aureus was the most common pathogen (31.2%). The mitral (41.1%) and aortic (37.6%) valves were infected most commonly. The following complications were common: stroke (16.9%), embolization other than stroke (22.6%), heart failure (32.3%), and intracardiac abscess (14.4%). Surgical therapy was common (48.2%), and in-hospital mortality remained high (17.7%). Prosthetic valve involvement (odds ratio, 1.47; 95% confidence interval, 1.13-1.90), increasing age (1.30; 1.17-1.46 per 10-year interval), pulmonary edema (1.79; 1.39-2.30), S aureus infection (1.54; 1.14-2.08), coagulase-negative staphylococcal infection (1.50; 1.07-2.10), mitral valve vegetation (1.34; 1.06-1.68), and paravalvular complications (2.25; 1.64-3.09) were associated with an increased risk of in-hospital death, whereas viridans streptococcal infection (0.52; 0.33-0.81) and surgery (0.61; 0.44-0.83) were associated with a decreased risk. CONCLUSIONS: In the early 21st century, IE is more often an acute disease, characterized by a high rate of S aureus infection. Mortality remains relatively high.
BACKGROUND: We sought to provide a contemporary picture of the presentation, etiology, and outcome of infective endocarditis (IE) in a large patient cohort from multiple locations worldwide. METHODS: Prospective cohort study of 2781 adults with definite IE who were admitted to 58 hospitals in 25 countries from June 1, 2000, through September 1, 2005. RESULTS: The median age of the cohort was 57.9 (interquartile range, 43.2-71.8) years, and 72.1% had native valve IE. Most patients (77.0%) presented early in the disease (<30 days) with few of the classic clinical hallmarks of IE. Recent health care exposure was found in one-quarter of patients. Staphylococcus aureus was the most common pathogen (31.2%). The mitral (41.1%) and aortic (37.6%) valves were infected most commonly. The following complications were common: stroke (16.9%), embolization other than stroke (22.6%), heart failure (32.3%), and intracardiac abscess (14.4%). Surgical therapy was common (48.2%), and in-hospital mortality remained high (17.7%). Prosthetic valve involvement (odds ratio, 1.47; 95% confidence interval, 1.13-1.90), increasing age (1.30; 1.17-1.46 per 10-year interval), pulmonary edema (1.79; 1.39-2.30), S aureus infection (1.54; 1.14-2.08), coagulase-negative staphylococcal infection (1.50; 1.07-2.10), mitral valve vegetation (1.34; 1.06-1.68), and paravalvular complications (2.25; 1.64-3.09) were associated with an increased risk of in-hospital death, whereas viridans streptococcal infection (0.52; 0.33-0.81) and surgery (0.61; 0.44-0.83) were associated with a decreased risk. CONCLUSIONS: In the early 21st century, IE is more often an acute disease, characterized by a high rate of S aureus infection. Mortality remains relatively high.
Authors: J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey Journal: Clin Infect Dis Date: 2000-04-03 Impact factor: 9.079
Authors: J Bishara; L Leibovici; D Gartman-Israel; A Sagie; A Kazakov; E Miroshnik; S Ashkenazi; S Pitlik Journal: Clin Infect Dis Date: 2001-10-10 Impact factor: 9.079
Authors: Christopher H Cabell; James G Jollis; Gail E Peterson; G Ralph Corey; Deverick J Anderson; Daniel J Sexton; Christopher W Woods; L Barth Reller; Thomas Ryan; Vance G Fowler Journal: Arch Intern Med Date: 2002-01-14
Authors: Timothy S Naimi; Kathleen H LeDell; Kathryn Como-Sabetti; Stephanie M Borchardt; David J Boxrud; Jerome Etienne; Susan K Johnson; Francois Vandenesch; Scott Fridkin; Carol O'Boyle; Richard N Danila; Ruth Lynfield Journal: JAMA Date: 2003-12-10 Impact factor: 56.272
Authors: Vance G Fowler; Maren K Olsen; G Ralph Corey; Christopher W Woods; Christopher H Cabell; L Barth Reller; Allen C Cheng; Tara Dudley; Eugene Z Oddone Journal: Arch Intern Med Date: 2003-09-22
Authors: Bruno Hoen; François Alla; Christine Selton-Suty; Isabelle Béguinot; Anne Bouvet; Serge Briançon; Jean-Paul Casalta; Nicolas Danchin; François Delahaye; Jerome Etienne; Vincent Le Moing; Catherine Leport; Jean-Luc Mainardi; Raymond Ruimy; François Vandenesch Journal: JAMA Date: 2002-07-03 Impact factor: 56.272
Authors: Fred C Tenover; Linda M Weigel; Peter C Appelbaum; Linda K McDougal; Jasmine Chaitram; Sigrid McAllister; Nancye Clark; George Killgore; Caroline M O'Hara; Laura Jevitt; Jean B Patel; Bülent Bozdogan Journal: Antimicrob Agents Chemother Date: 2004-01 Impact factor: 5.191
Authors: Batu K Sharma-Kuinkel; Yuling Wu; David E Tabor; Hoyin Mok; Bret R Sellman; Amy Jenkins; Li Yu; Hasan S Jafri; Thomas H Rude; Felicia Ruffin; Wiley A Schell; Lawrence P Park; Qin Yan; Joshua T Thaden; Julia A Messina; Vance G Fowler; Mark T Esser Journal: J Clin Microbiol Date: 2014-11-12 Impact factor: 5.948
Authors: G Béraud; G Le Moal; A Elsendoorn; P Tattevin; C Godet; S Alfandari; W Couet; P Roblot; F Roblot Journal: Eur J Clin Microbiol Infect Dis Date: 2011-10-29 Impact factor: 3.267
Authors: B Zaloudíková; E Němcová; J Pol; Z Sorm; S Wurmová; K Novotná; M Vaněrková; V Holá; F Růžička; L Dušek; P Němec; T Freiberger Journal: Eur J Clin Microbiol Infect Dis Date: 2011-10-02 Impact factor: 3.267
Authors: M Carugati; C A Petti; C Arnold; J M Miro; J M Pericàs; C Garcia de la Maria; Z Kanafani; E Durante-Mangoni; J Baddley; D Wray; J L Klein; F Delahaye; N Fernandez-Hidalgo; M M Hannan; D Murdoch; A Bayer; V H Chu Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191